Go Pro
OTCMKTS:CPHRF

Cipher Pharmaceuticals (CPHRF) Stock Price, News & Analysis

Cipher Pharmaceuticals logo
$10.21 +0.01 (+0.10%)
As of 01:21 PM Eastern

About Cipher Pharmaceuticals Stock (OTCMKTS:CPHRF)

Advanced

Key Stats

Today's Range
$10.21
$10.24
50-Day Range
$10.08
$12.80
52-Week Range
$8.92
$15.00
Volume
380 shs
Average Volume
5,257 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company that develops, acquires and commercializes prescription products in respiratory and dermatology markets. Founded in 2004 and headquartered in Vancouver, British Columbia, the company focuses on in-licensing established therapies and launching them under its own commercial infrastructure in North America.

In the respiratory segment, Cipher markets generic inhalation therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD). These include dry-powder inhalers (DPIs) and metered-dose inhalers (MDIs) that offer patients lower-cost alternatives to branded drugs. In dermatology, the company has brought to market treatments addressing acne, fungal infections of the nails and other skin disorders, often through licensing agreements with innovator companies.

Cipher operates primarily in Canada and the United States. Its business model emphasizes strategic partnerships and licensing arrangements, enabling the company to secure exclusive Canadian rights to new products while collaborating with third-party partners for U.S. commercialization. This approach allows Cipher to leverage established regulatory approvals and focus resources on market access, sales and marketing.

Looking ahead, Cipher continues to expand its product pipeline through in-licensing and development of both generic and branded prescription drugs. The company is advancing new formulations in respiratory care and exploring additional dermatology assets, aiming to build a diversified specialty pharmaceutical portfolio that delivers growth through product launches and ongoing royalty streams.

AI Generated. May Contain Errors.

Receive CPHRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CPHRF Stock News Headlines

Cipher Pharmaceuticals Balances U.S. Strain With Epuris Strength
A glass of water could power your entire life??
MIT materials science students say a single glass of water could generate enough energy to power a person for their entire life, a discovery that just won the school's grand prize. The U.S. President has already issued four executive orders directing resources toward this emerging energy technology, and one company sits at the center of the shift. A major announcement expected November 4th could bring renewed attention to this company.tc pixel
Cipher Pharmaceuticals Inc CPHRF
See More Headlines

CPHRF Stock Analysis - Frequently Asked Questions

Cipher Pharmaceuticals' stock was trading at $10.98 at the beginning of 2026. Since then, CPHRF shares have decreased by 6.7% and is now trading at $10.24.

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) posted its quarterly earnings data on Thursday, May, 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.06. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $10.87 million.

Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/05/2016
Today
8/26/2026
Next Earnings (Estimated)
11/05/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:CPHRF
Previous Symbol
NASDAQ:CPHR
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (OTCMKTS:CPHRF) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners